טוען...
Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients
BACKGROUND AND AIMS: Chronic hepatitis C (HCV) is a liver disease affecting over 3 million Americans. Liver biopsy is the gold standard for assessing liver fibrosis and is used as a benchmark for initiating treatment, though it is expensive and carries risks of complications. FibroTest is a non-inva...
שמור ב:
| Main Authors: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Public Library of Science
2011
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3229483/ https://ncbi.nlm.nih.gov/pubmed/22164204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0026783 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|